Abstract YO23
Case summary
Soft tissue Giant cell tumor presented as Nasopharyngeal mass : A case Report
ABSTRACT:
Background:
Primary soft tissue giant cell tumors are exceedingly rare. These often present in the elderly and are mostly noted on the extremities. Morphologically, these tumors resemble their osseous counterparts but sequencing studies have suggested that these two may be genetically distinct. Surgical extirpation remains standard of treatment; but for those with unresectable disease treatment options are less clear. For these patients, the use of bisphosphonates and RANK-L directed biologic therapy have been reported in the literature.
Case presentation:
A 30 year old male consulted at our medical oncology clinic with the chief complaint of diplopia. Magnetic resonance imaging (MRI) of the head revealed an enhancing soft tissue mass at the nasopharyngeal wall measuring 5.8x5.5x5.1cm extending anteriorly at the posterior margin of the nasal cavity, both parasellar regions, leptomeningeal region of the medial aspect of both middle cranial fossa, and infiltrating into the clivus. No distant metastasis was seen. Punch biopsy of this nasopharyngeal mass favored a giant cell tumor. Immunohistochemical staining was done with the following results: Cytokeratin negative, CD68 positive, and Vimentin positive, all consistent with giant cell tumor. Due to its location, the tumor was regarded to be unresectable. Zoledronic acid was given once every 28 days for 3 months. Cranial CT scan done after three months of treatment revealed an enhancing nasopharyngeal mass measuring 6.0x5.0x4.0cm with intracranial extension. At this time despite demonstrating stable disease, the patient was noted to have worsening of symptoms and was then shifted to Denosumab.
Conclusion:
We have reported a case of a nasopharyngeal giant cell tumor, which is an uncommon presentation of a rare soft tissue tumor. While surgery is the preferred treatment for this disease, the location of this tumor precluded resection. This has prompted the decision to employ systemic treatment with Zoledronic acid and subsequently Denosumab for this patient.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
134P - Identification, development and validation of a circulating miRNA-based diagnostic signature for early detection of gastric cancer
Presenter: Daisuke Izumi
Session: Poster display session
Resources:
Abstract
135P - The promising key genes associated with tumour microenvironment and prognosis of hepatocellular carcinoma
Presenter: Jing Fang
Session: Poster display session
Resources:
Abstract
136P - Helicobacter pylori-positive gastric diffuse large B-cell lymphoma: A subset with distinct prognostic features
Presenter: Yuan Cheng
Session: Poster display session
Resources:
Abstract
137P - Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer
Presenter: Zuhua Chen
Session: Poster display session
Resources:
Abstract
138P - Incidence of supracarinal lymph node positivity in operated cases of total esophagectomy: Short term results from a tertiary cancer centre
Presenter: Akhil Palod
Session: Poster display session
Resources:
Abstract
139P - Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy
Presenter: Ayberk Besen
Session: Poster display session
Resources:
Abstract
140P - Pancreaticoduodenectomy versus combined neoadjuvant chemotherapy and pancreaticoduodenectomy: Survival patterns among patients with stage II & III periampullary carcinoma
Presenter: Mai Abdelkader
Session: Poster display session
Resources:
Abstract
141P - A 13-gene signature of DNA repair predicts prognosis in gastric cancer patients
Presenter: Jinjia Chang
Session: Poster display session
Resources:
Abstract
142P - Relation between Interleukin -4 (590C/T) gene polymorphism and hepatocellular carcinoma risk in HBV and HCV patients
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract